Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Minerva Neuroscie (NQ: NERV )

3.440 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.440
Bid (Size) 3.260 (7)
Ask (Size) 3.890 (6)
Prev. Close 3.440
Today's Range 3.440 - 3.440
52wk Range 2.260 - 13.49
Shares Outstanding 6,993,406
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NERV Stock Earnings: Minerva Neurosciences Beats EPS for Q1 2024
NERV stock results show that Minerva Neurosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire

Performance

YTD
-44.07%
-44.07%
1 Month
+39.84%
+39.84%
3 Month
+32.82%
+32.82%
6 Month
-47.48%
-47.48%
1 Year
-44.96%
-44.96%

More News

Read More
Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Regulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More Data
Via Benzinga
Exposures Product Safety
Minerva Neurosciences: Q4 Earnings Insights
Via Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Crude Oil Gains 1%; Macy's Plans To Close 150 Stores
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Nasdaq Rises 50 Points; Lowe's Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
10 Short Squeeze Stocks To Watch: Baosheng Media, Toro Corp, Getty Images And More
Via Benzinga
Top 5 Health Care Stocks That May Collapse This Quarter
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Via Benzinga
Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On Thursday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Crude Oil Rises Sharply; Unifirst Earnings Miss Expectations
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.